Andrea Ulrichsen

ORCID: 0000-0003-3522-0620
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bipolar Disorder and Treatment
  • Electroconvulsive Therapy Studies
  • Treatment of Major Depression
  • Mental Health Treatment and Access
  • Health Systems, Economic Evaluations, Quality of Life
  • Schizophrenia research and treatment
  • Archaeology and ancient environmental studies
  • Sleep and related disorders
  • Coordination Chemistry and Organometallics
  • Forensic Anthropology and Bioarchaeology Studies
  • Family Support in Illness
  • Adolescent and Pediatric Healthcare
  • Pleistocene-Era Hominins and Archaeology
  • Restless Legs Syndrome Research

King's College London
2021-2024

Bethlem Royal Hospital
2023

South London and Maudsley NHS Foundation Trust
2023

Australian National University
2022

Abstract Background Despite well-established guidelines for managing major depressive disorder, its extensive disability burden persists. This Value of Treatment mission from the European Brain Council aimed to elucidate nature and extent “gaps” between best-practice current-practice care, specifically to: 1. Identify current treatment gaps along care pathway determine these in comparison with stepped-care model 2. Recommend policies intending better meet patient needs (i.e., minimize gaps)....

10.1192/j.eurpsy.2022.28 article EN cc-by-nc-nd European Psychiatry 2022-01-01

Background Lithium has long been recognised as an effective treatment for bipolar disorder. Its relative efficacy measured with a diverse range of clinical outcomes, resulting in differences reporting that have not systematically reviewed. Aims We aimed to identify and compare the various measures lithium employed interventional studies people Method Database (PubMed, Web Science) hand searches were performed assessed response patients disorder who received lithium, up end 2021. included...

10.1192/bjo.2023.64 article EN cc-by-nc-nd BJPsych Open 2023-05-01

Abstract Background Major depressive disorder (MDD) is highly prevalent across Europe. While evidence-based treatments exist, many people with MDD have their condition undetected and/or untreated. This study aimed to assess the cost-effectiveness of reducing treatment gaps using a modeling approach. Methods A decision-tree model covering 27-month time horizon was used. followed care pathway where could be detected or not, and different forms provided. Expected costs pertaining Germany,...

10.1192/j.eurpsy.2023.2415 article EN cc-by-nc-nd European Psychiatry 2023-01-01
Coming Soon ...